At Piramal Pharma Solutions, our commitment to excellence is embodied by our esteemed “Science Collective”-a team of profoundly experienced and highly educated professionals dedicated to resolving the complex technical challenges our clients face. This elite group's extensive background in the pharmaceutical industry equips them with a nuanced understanding of the intricacies and hurdles inherent in pharmaceutical development.
As Vice President and Global API Technical Lead at Piramal Pharma Solutions, JF provides comprehensive scientific oversight and project orientation to our small molecule API business. JF is a vital cog in our API machine, providing guidance on all API/HPAPI projects developed and manufactured at our drug substance sites in the US, Canada, UK, and India. His input begins with the project evaluation, continues through development support, and culminates in the delivery of the API for our customers and their patients.
Over the past 25+ years, JF has built a highly regarded legacy of expertise in API development and manufacturing that spans experience on both the contract services and innovator company sides of drug development and manufacturing.
JF is available to share his expertise with our clients, in person or via a virtual session. To arrange a meeting send an email to jeanfrancois.carniaux@piramal.com.
Piramal Pharma Solutions is proud to include Brad Gold as a member of our Science Collective. Brad has an outstanding legacy of scientific excellence built over 30+ years in the industry. As our Global Formulations R&D Head, Brad provides complete scientific oversight for Piramal's drug product formulations business. He is an integral part of the operations at our formulation sites in the US, UK and India, and a valuable resource to all of our drug product customers.
Over the course of his career, Brad has established a proven track record of solving formulation and process challenges in pharmaceutical development, directing operations, containment design and implementation, continuous improvement, and people engagement.
Brad’s expertise is an asset that is available to all our clients, in person or via a virtual session. To arrange a meeting send an email to brad.gold@piramal.com.
Conor Barry, Ph.D., is the Global Biologics Technical Lead at Piramal Pharma Solutions. He leads our bioconjugate programs, leveraging his deep scientific and technical expertise to oversee critical research and drive successful outcomes.
With over 15 years of specialized experience in the field, Conor has played a pivotal role in the development and CMC filing of numerous bioconjugates. His exceptional technical acumen and strong leadership capabilities enable him to steer our bioconjugate initiatives through complex challenges, ultimately helping deliver transformative health solutions for patients.
Conor is passionate about enhancing patients’ lives. As an expert in bioconjugates, he offers his full support to customers working to develop groundbreaking treatments in the field. He is happy to consult with you in person or via a virtual session. To arrange a meeting, email conor@piramal.com.
Dr. Sundar Neelakantan is a key member of our esteemed Science Collective. Known to most as Sunny, Dr. Neelakantan is the Director of Development at Piramal Pharma Solutions' Lexington, Kentucky facility. In this pivotal role, he oversees all formulation and analytical development activities, providing technical direction, training, and mentorship to the site's teams.
Sunny plays a crucial role in business development, engaging with clients to support Requests for Proposals (RFPs), reviewing proposals, and guiding the successful launch of new projects. He expertly manages and monitors project progress to ensure milestones are achieved on time while maintaining budgetary constraints and optimizing revenue. Sunny facilitates the Lexington site's critical role in our integrated ADCelerate&trade program as the sterile fill/finish facility, actively contributing to its work on ADCelerate&trade initiatives.
With over 23 years of experience in the pharmaceutical industry, Sunny's expertise spans a wide range of drug products, including small molecules, peptides, and biologics. He has extensive experience in clinical and commercial manufacturing of high-potent drug products using isolator-based technology. His specialization includes lyophilization cycle development (aqueous and co-solvent-based), liposomal formulation, lipid-based nano-emulsions and nanoparticles, and micro suspensions. He is an expert in product development, applying Quality by Design (QbD) principles, CMC regulatory strategy, FMEA, and technical risk assessment.
Each member of the Science Collective has advanced degrees in relevant fields, ensuring a foundation of knowledge that is both deep and broad. Their educational achievements are complemented by substantial hands-on technical experience, having honed their expertise across leading CDMOs. This combination of theoretical knowledge and practical experience makes our team uniquely capable of navigating the multifaceted challenges presented in drug development.
They approach each challenge with a solution-oriented mindset, ready to tackle even the most daunting of problems. Whether it involves small molecules, peptides, Antibody Drug Conjugates (ADCs), or biologics, our team ensures that no issue goes unaddressed, accelerating project timelines and enhancing the overall development process. Furthermore, their multidisciplinary approach spans a wide array of domains, from synthetic chemistry to process development to commercial manufacturing, enabling them to provide comprehensive solutions across the entire spectrum of drug development. This versatility not only enhances our service offering but also reinforces our commitment to meeting patient needs with precision and efficiency.
By entrusting your project to the Science Collective at Piramal Pharma Solutions, you gain more than just expert service you acquire a proactive partnership dedicated to your project's success, from conception through to commercialization.
